Clinical Trials

2,000 enrolled

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03672539 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

50 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03737955 2026-01-28

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

36 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT05955261 2025-12-09

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

70 enrolled

Leukemia, Myeloid, Acute

NCT03589729 2025-11-20

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

MyeloidOther hematologic neoplasmSarcoma

100 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT04050280 2025-05-01

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

39 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT03839446 2025-02-20

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

16 enrolled 13 charts

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute

NCT05599360 2024-12-02

Vyxeos for Induction of Low- or Intermediate-risk.

20 enrolled

Leukemia, Myeloid, Acute

NCT05904106 2024-12-02

VINCENT

146 enrolled

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03374332 2024-02-08

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

11 enrolled

Recurrence, Leukemia, Myeloid, Acute, Disease Progression

NCT02117297 2023-10-26

SCT Plus Immune Therapy in Average Risk AML/MDS

26 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02221310 2023-10-26

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

25 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00005962 2023-06-22

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

NCT04173585 2023-03-27

TEAM

50 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT04326439 2022-06-15

AflacLL1901 (CHOA-AML)

Phase 2 Terminated

8 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT01548911 2018-07-02

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Phase 2 Withdrawn

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

NCT00673153 2017-06-01

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2 Terminated

31 enrolled 11 charts

LymphoidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00798213 2015-02-04

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Phase 2 Terminated

29 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00017589 2014-01-06

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Leukemia, Leukemia, Myeloid, Acute

NCT00882102 2013-09-13

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

43 enrolled 5 charts

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00195000 2013-06-19

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

43 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00968071 2013-03-08

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

71 enrolled 5 charts

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00037596 2013-02-13

Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT00003673 2012-08-22

CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse

55 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT00006122 2012-07-16

Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

106 enrolled

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00089050 2011-11-30

Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia